Pillsbury Advises Cori Clinical on $4 Million Seed Funding Round

Cori Clinical is an AI workspace that combines an organization’s accumulated clinical trial knowledge with external intelligence from clinical trial registries, regulatory guidance and public sources, including the Food and Drug Administration, the Medicines and Healthcare products Regulatory Agency and the European Medicines Agency.

The funding will expand Cori’s delivery capacity, support team growth, including the appointment of Dr. Emma Ogburn as chief clinical officer, and enhance the platform’s regulatory and clinical intelligence. It will also help Cori build on customer traction and turn growing interest from clinical research organizations and pharmaceutical companies into broader, deeper commercial relationships.

To learn more about the transaction, click here.

“It was a pleasure to advise Cori Clinical on this seed round,” said Emerging Companies & Venture Capital partner Sarah Melaney, who led the transaction. “Bringing clinical trial knowledge and regulatory intelligence together has clear potential to help teams make better-informed decisions. This transaction also reflects Pillsbury’s growing emerging companies and venture capital practice, supporting ambitious businesses at the intersection of technology and life sciences. We look forward to seeing Cori build on its early customer traction as it expands its team and platform.”

In addition to Melaney, the Pillsbury deal team included senior associate Alex Davidson and associate Will Dunlop.